Alnwick, UK-based Arcinova will now have access to Sterling Pharma Solutions’ scale up and pilot plant assets, which will complement the company’s existing facilities. Sterling Pharma Solutions is headquartered in Cramlington, UK and is just 28 miles from the Arcinova site.
The facilities include pilot plant assets ranging from 50lt up to 1300lt capacity, with 5-100kg batch generation capability. The combined service offering will allow Arcinova to ensure technical transfer from grams to 100’s kilogram scale and is designed to ensure an integrated facility to meet clients’ drug substance requirements, from preclinical through to full scale commercial launch phases.
The scale up process will be executed by trained Arcinova personnel, supported by the long-established skills, infrastructure and capacity of Sterling Pharma Solutions. Both organisations are very experienced in the provision of secure sources of supply for technically challenging projects.
Arcinova provides both integrated end to end solutions and standalone services to pharmaceutical and biotech companies. It works across drug substance synthesis, drug product manufacture, CMC, bioanalytical and metabolism services, radiolabelling synthesis, and synthesis of toxic/highly potent Active Pharmaceutical Ingredients (APIs). It also provides consultancy services and works in partnership with companies throughout the drug development process.
Sterling Pharma Solutions is a provider of small molecule API development and manufacturing services to the global pharmaceutical industry.
Ian Shott CBE, CEO of Arcinova and investor/director at Sterling Pharma Solutions said: “I’m delighted that Arcinova and Sterling Pharma Solutions have forged this partnership: by working in collaboration and combining expertise and specialist capabilities, we can offer an even wider ranging service to the global pharmaceutical and biotechnology communities and further strengthen the level of support we offer to our clients.”
Kevin Cook, CEO at Sterling Pharma Solutions added: “This collaboration brings together complementary capabilities to make the North East of England the right choice for pharmaceutical development, scale-up, and commercial manufacture.”